In this study, we found that the genetic SCN5A T220I variant acts like a lifelong sodium channel blocker, mostly providing protection from diverse cardiac arrhythmias, while also increasing risk of bradyarrhythmias, similar to sodium channel blocker side effects. This evidence concerns the gene SCN5A and cardiac rhythm disease.